Caribou Biosciences, Inc. reported Q4 and full year 2025 financial results, including licensing and collaboration revenue of $3.9 million and $11.2 million, respectively, R&D expenses of $23.8 million and $109.4 million, and GAAP net loss of $26.5 million ($0.28 per share) and $148.1 million ($1.59 per share). The company provided clinical updates on vispa-cel and CB-011 programs and $142.8 million in cash as of December 31, 2025, sufficient into 2H 2027.
Key takeaways
Licensing and collaboration revenue $3.9M Q4 2025 vs $2.1M Q4 2024, $11.2M full year 2025 vs $10.0M 2024
R&D expenses $23.8M Q4 2025 vs $30.5M Q4 2024, $109.4M full year 2025 vs $130.2M 2024
GAAP net loss $26.5M or $0.28/share Q4 2025 vs $35.5M or $0.39/share Q4 2024
GAAP net loss $148.1M or $1.59/share full year 2025 vs $149.1M or $1.65/share 2024
Cash, cash equivalents, and marketable securities $142.8M as of Dec 31, 2025 vs $249.4M Dec 31, 2024
Non-recurring non-cash impairment charges $21.3M full year 2025
vispa-cel ANTLER phase 1 data presented Feb 5, 2026; longer follow-up expected 2026
CB-011 CaMMouflage dose expansion ongoing; initial data expected 2026